Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma (CSCC) post-surgery. Adjuvant treatment with cemiplimab (Libtayo ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

The EC approved Libtayo – a fully human monoclonal ... (SCC), advanced basal cell carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC), and advanced non-small cell lung cancer ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Libtayo became Regeneron's latest blockbuster ... We also plan to seek regulatory approval for high risk adjuvant cutaneous squamous cell carcinoma, a setting in which KEYTRUDA failed and over ...